1. Risk of Pacemaker Implantation After Degenerative Mitral and Concomitant Tricuspid Valve Surgery.
- Author
-
Brescia AA, Wagner CM, Meldrum DE, Watt TMF, Hawkins RB, Green CJ, Romano MA, Bolling SF, and Ailawadi G
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, Tricuspid Valve surgery, Middle Aged, Mitral Valve surgery, Postoperative Complications epidemiology, Cardiac Valve Annuloplasty methods, Risk Assessment, Heart Valve Prosthesis Implantation methods, Treatment Outcome, Mitral Valve Insufficiency surgery, Mitral Valve Insufficiency mortality, Tricuspid Valve Insufficiency surgery, Pacemaker, Artificial
- Abstract
Background: A recent multicenter trial showed a reduction in tricuspid regurgitation (TR) progression when tricuspid annuloplasty was performed at the time of surgery for degenerative mitral regurgitation (MR), but with a 14% permanent pacemaker (PPM) rate. We present real-world outcomes at a high-volume center for degenerative MR surgery with/without tricuspid annuloplasty., Methods: Patients undergoing first-time degenerative mitral surgery between 2011 and 2021 were identified (n = 1738). After excluding patients undergoing aortic, aortic valve, or tricuspid replacement procedures, patients were stratified into mitral surgery alone (n = 1068) vs mitral surgery plus tricuspid annuloplasty (n = 417). Outcomes, including operative mortality, new PPM implantation, postoperative length of stay, and risk-adjusted overall mortality, were compared., Results: Among 1485 patients in this study, 98% underwent mitral repair. Compared with concomitant tricuspid annuloplasty patients, those undergoing mitral surgery alone were 6 years younger and had lower median The Society of Thoracic Surgeons predicted risk of mortality. Among concomitant tricuspid repair patients, 85% (355 of 417) had moderate or less preoperative TR, whereas 15% (61 of 417) had severe TR. Operative mortality was 1.4%. The incidence of new PPM implantation was 0.7% (7 of 1068) in the mitral only group and 5.5% (23 of 417) in the concomitant tricuspid group (P < .001). Although unadjusted cumulative survival was lower in the concomitant tricuspid group, after risk adjustment, concomitant tricuspid surgery was not associated with worse overall mortality (hazard ratio, 0.80; 95% CI, 0.53-1.19; P = .27)., Conclusions: Concomitant tricuspid annuloplasty is safe, with no difference in mortality and a <6% PPM rate at a high-volume mitral center. These data provide real-world context for concomitant tricuspid annuloplasty., Competing Interests: Disclosures Alexander A. Brescia is an Associate Editor for Digital Media and Digital Scholarship for The Annals of Thoracic Surgery. Matthew A. Romano reports a relationship with Edwards that includes: Consulting or advisory. Gorav Ailawadi reports a relationship with Edwards that includes: Consulting or advisory; with Abbott that includes: Consulting or advisory; with Medtronic that includes: Consulting or advisory; with Philips that includes: Consulting or advisory; with Arthrex that includes: Consulting or advisory. The other authors have no conflicts of interest to disclose., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF